GlassScriptPhysician profile
Michael Favila
NPI 1447781521
$7,681.27
in general payments reported to CMS, 2019-2025
40 companies · $1,523 in 2025
The $1,523 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.42 · 2020: $351 · 2021: $1,605 · 2022: $1,487 · 2023: $1,264 · 2024: $1,421 · 2025: $1,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,208.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,517.11 | 2021-2025 | |
| Novo Nordisk INC | $977.40 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $746.86 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $575.85 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $535.01 | 2021-2025 | |
| Pfizer INC. | $418.59 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.16 | 2021-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $309.84 | 2021-2024 | Xarelto |
| Orexo US, INC. | $225.77 | 2022-2025 | Zubsolv |
| Collegium Pharmaceutical, INC. | $187.82 | 2020-2025 | Xtampza, Belbuca |
| Amgen INC. | $166.22 | 2020-2022 | |
| Indivior INC. | $153.24 | 2021-2025 | Sublocade |
| Almatica Pharma LLC | $141.33 | 2021-2024 | Loreev Xr, Sertraline Hcl, Gralise |
| Otsuka America Pharmaceutical, INC. | $120.11 | 2020-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $113.57 | 2022-2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Favila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.